Activity-based synthetic biomarkers that selectively leverage protease activity in tumors have yielded amplified signals and outperformed blood biomarkers in detecting smaller tumors in several preclinical models, such as carcinoembryonic antigen in colorectal cancer (32) and human epididymis protein 4 in ovarian cancer (33). The gene discussed is CEACAM5; the disease is ovarian cancer.